Baseline characteristics of patients enrolled in the PETHEMA/GEM2012MENOS65 clinical trial with data on CAs
| . | Total (N = 390) . |
|---|---|
| Median age (range), y | 58 (31-65) |
| Sex, n (%) | |
| Male | 207 (53) |
| Female | 183 (47) |
| ECOG performance status, n (%) | |
| 0 | 160 (41) |
| 1 | 156 (40) |
| 2 | 55 (14) |
| 3 | 15 (4) |
| Data missing | 4 (1) |
| M-protein type, n (%) | |
| IgG | 231 (59) |
| IgA | 94 (24) |
| Light chain | 56 (15) |
| IgD | 4 (1) |
| Nonsecretory | 5 (1) |
| ISS stage, n (%) | |
| I | 155 (40) |
| II | 134 (34) |
| III | 96 (25) |
| Data missing | 5 (1) |
| R-ISS stage, n (%) | |
| I | 114 (29) |
| II | 234 (60) |
| III | 23 (6) |
| Data missing | 19 (5) |
| High-risk CAs, n (%) | |
| t(4;14) | 42 (47) |
| t(14;16) | 10 (11) |
| del(17p13) | 38 (42) |
| Median follow-up, months | 40 |
| . | Total (N = 390) . |
|---|---|
| Median age (range), y | 58 (31-65) |
| Sex, n (%) | |
| Male | 207 (53) |
| Female | 183 (47) |
| ECOG performance status, n (%) | |
| 0 | 160 (41) |
| 1 | 156 (40) |
| 2 | 55 (14) |
| 3 | 15 (4) |
| Data missing | 4 (1) |
| M-protein type, n (%) | |
| IgG | 231 (59) |
| IgA | 94 (24) |
| Light chain | 56 (15) |
| IgD | 4 (1) |
| Nonsecretory | 5 (1) |
| ISS stage, n (%) | |
| I | 155 (40) |
| II | 134 (34) |
| III | 96 (25) |
| Data missing | 5 (1) |
| R-ISS stage, n (%) | |
| I | 114 (29) |
| II | 234 (60) |
| III | 23 (6) |
| Data missing | 19 (5) |
| High-risk CAs, n (%) | |
| t(4;14) | 42 (47) |
| t(14;16) | 10 (11) |
| del(17p13) | 38 (42) |
| Median follow-up, months | 40 |
ECOG, Eastern Cooperative Oncology Group.